agilon health, inc. Payments to Acquire Loans Receivable
agilon health, inc. (AGL) reported Payments to Acquire Loans Receivable of $13.73 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireLoansReceivable · last filed 2025-02-25
- agilon health, inc. payments to acquire loans receivable for the quarter ending 2024-03-31 was $8.51M, a 553.96% increase year-over-year.
- agilon health, inc. payments to acquire loans receivable for the quarter ending 2023-12-31 was $10.75M, a 437.50% increase year-over-year.
- agilon health, inc. payments to acquire loans receivable for the quarter ending 2023-09-30 was $310.00K.
- agilon health, inc. payments to acquire loans receivable for the quarter ending 2023-06-30 was $7.17M, a 102285.71% increase year-over-year.
- agilon health, inc. payments to acquire loans receivable for fiscal 2024 was $13.73M, a 29.68% decline from fiscal 2023.
- agilon health, inc. payments to acquire loans receivable for fiscal 2023 was $19.53M, a 199.97% increase from fiscal 2022.
- agilon health, inc. payments to acquire loans receivable for fiscal 2022 was $6.51M, a 92.14% decline from fiscal 2021.
- agilon health, inc. payments to acquire loans receivable for fiscal 2021 was $82.83M, a 2053.13% increase from fiscal 2020.
| Period end | Payments to Acquire Loans Receivable 3 month | Payments to Acquire Loans Receivable 6 month | Payments to Acquire Loans Receivable 9 month | Payments to Acquire Loans Receivable 12 month |
|---|---|---|---|---|
| 2024-12-31 | $13.73M 10-K · filed 2025-02-25 | |||
| 2024-03-31 | $8.51M 10-Q · filed 2024-05-07 | $19.26M derived: sum of 2 quarters · filed 2025-02-25 | $19.57M derived: sum of 3 quarters · filed 2025-02-25 | $26.73M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-12-31 | $10.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $11.06M derived: sum of 2 quarters · filed 2025-02-25 | $18.23M derived: sum of 3 quarters · filed 2025-02-25 | $19.53M 10-K · filed 2025-02-25 |
| 2023-09-30 | $310.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $7.48M derived: sum of 2 quarters · filed 2023-11-02 | $8.78M 10-Q · filed 2023-11-02 | $10.78M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $7.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $8.47M 10-Q · filed 2023-08-03 | $10.47M derived: sum of 3 quarters · filed 2025-02-25 | $10.47M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $1.30M 10-Q · filed 2024-05-07 | $3.30M derived: sum of 2 quarters · filed 2025-02-25 | $3.30M derived: sum of 3 quarters · filed 2025-02-25 | $3.31M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $2.00M derived: sum of 2 quarters · filed 2025-02-25 | $2.01M derived: sum of 3 quarters · filed 2025-02-25 | $6.51M 10-K · filed 2025-02-25 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $7.00K derived: sum of 2 quarters · filed 2023-11-02 | $4.51M 10-Q · filed 2023-11-02 | $10.73M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $4.51M 10-Q · filed 2023-08-03 | $10.73M derived: sum of 3 quarters · filed 2024-02-27 | $17.03M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $4.50M 10-Q · filed 2023-05-09 | $10.72M derived: sum of 2 quarters · filed 2024-02-27 | $17.03M derived: sum of 3 quarters · filed 2024-02-27 | $86.13M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $6.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $12.52M derived: sum of 2 quarters · filed 2024-02-27 | $81.63M derived: sum of 3 quarters · filed 2024-02-27 | $82.83M 10-K · filed 2024-02-27 |
| 2021-09-30 | $6.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $75.41M derived: sum of 2 quarters · filed 2022-11-03 | $76.61M 10-Q · filed 2022-11-03 | $78.15M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $69.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $70.31M 10-Q · filed 2022-08-04 | $71.85M derived: sum of 3 quarters · filed 2023-03-01 | $71.99M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $1.20M 10-Q · filed 2022-05-05 | $2.74M derived: sum of 2 quarters · filed 2023-03-01 | $2.88M derived: sum of 3 quarters · filed 2023-03-01 | $4.69M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $1.68M derived: sum of 2 quarters · filed 2023-03-01 | $3.49M derived: sum of 3 quarters · filed 2023-03-01 | $3.85M 10-K · filed 2023-03-01 |
| 2020-09-30 | $142.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $1.95M derived: sum of 2 quarters · filed 2021-10-28 | $2.31M 10-Q · filed 2021-10-28 | |
| 2020-06-30 | $1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $2.17M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $359.00K 10-Q · filed 2021-05-26 | |||
| 2019-12-31 | $1.15M 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |